PresentationMatthew GlineCEO & Director Yes. Thanks for having us. I'm very aware there's like a large 40-minute timer here that's counting down slowly. So I'm aware of the time to fill. We have a lot to say, though. So look, I'm the CEO of Roivant. We are a biopharma company. I think most are probably at least somewhat familiar with us. We mostly focus on development-stage drug development, clinical stage drug development. And today, we have a portfolio of several quite late-stage clinical programs, one of ...

Question-and-Answer SessionJason GerberryBofA Securities, Research Division Imagine you're sleeping a little bit better. I know you're a little nervous about placebo effects and things like that going into the data, but now that everything is sorted out and you've got the result that you wanted. Maybe that's a good place to start is talking about that data. And if you want to maybe just contextualize that data, what it means for patients, how doctors you think will interpret the data and what that means for ...

Roivant Sciences (NasdaqGS:ROIV) 2025 Conference September 24, 2025 05:45 AM ET Company ParticipantsMatt Gline - CEOConference Call ParticipantsJason Gerberry - Equity Research AnalystJason GerberryWelcome, everybody, and thanks for joining us here at the BofA Global Healthcare Conference in London. My name is Jason Gerberry. I'm one of the SMID-cap biotech analysts. Pleased to be introducing our next company presenter, Roivant, and CEO, Matt Gline. Matt, thanks for joining us.Matt GlineThanks for having me ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock characte ...

评级与目标价调整 - 花旗将Roivant Sciences评级调整为中性 维持持有操作 当时股价为15.47美元 [1] - 美国银行将Roivant目标价从12美元上调至16.50美元 [1][6] 临床研究进展 - 公司公布brepocitinib治疗皮肌炎的三期VALOR研究取得积极结果 在主要终点和全部九个关键次要终点均显示显著改善 [2] - 30mg每日剂量组第52周总改善评分(TIS)达46.5 显著优于安慰剂组的31.2 (p=0.0006) [3] - 超过三分之二患者达到至少中等应答 近半数患者实现主要应答 [3] 监管申请计划 - 计划在2026年上半年提交新药申请(NDA) [4][6] - brepocitinib显示出持续的安全性特征 [4] 股价与交易表现 - 当前股价14.99美元 较前下跌1.93%或0.30美元 [4] - 当日交易区间为14.98-15.52美元 [4] - 年內最高价16.05美元 最低价8.73美元 [5] - 当前市值约102.3亿美元 [5] - 当日成交量2,323,718股 显示投资者活跃兴趣 [5]

Roivant Sciences Ltd. (ROIV) shares ended the last trading session 7.8% higher at $15.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 20.6% gain over the past four weeks.Roivant shares gained after the company, along with its partner, Priovant Therapeutics, announced that their investigational candidate, brepocitinib, met the primary endpoint and all nine key secondary endpoints, with statistical significance, ...

PresentationLadies and gentlemen, thank you for standing by. Welcome to VALOR Phase III study results [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn the conference over to Stephanie Lee. Please go ahead.Stephanie Lee GriffinChief Operating Officer of Roivant Platforms Good morning, and thanks for joining today's call to review the VALOR Phase III study results. I'm Stephanie Lee with Roivant. Presenting today, we have Matt Gline, CEO of Roivant; ...

主要股指表现 - 标普500指数下跌0.17% 道琼斯工业指数上涨0.77% 纳斯达克100指数下跌0.80% [1] - 欧洲斯托克50指数上涨0.11% 中国上证综指上涨0.37% 日经225指数下跌0.25% [6] 美联储政策与利率 - 美联储批准25个基点降息 预计年底前还将进行两次降息 [1] - 市场预期FOMC会议将降息25个基点 关注点阵图是否显示年内累计降息约70个基点 [5] - 10年期美债收益率上升0.6个基点至4.034% [7] 住房市场数据 - 8月新屋开工月率下降8.5%至130.7万套 低于预期的136.5万套 [3] - 8月建筑许可月率意外下降3.7%至131.2万套 创5.25年新低 低于预期的137万套 [3] - 9月12日当周MBA抵押贷款申请增长29.7% 其中购房抵押贷款子指数增长2.9% 再融资子指数大幅增长57.7% [4] - 30年期固定抵押贷款利率下降10个基点至6.39% 创11个月新低 [4] 科技股与芯片板块 - 英伟达下跌超过2% 因中国网信办要求大型企业终止RTX Pro 6000D芯片订单 [2][11] - 科技七巨头普遍下跌 亚马逊、特斯拉和Meta跌幅超1% Alphabet下跌0.77% 微软下跌0.34% [12] - Workday上涨超过8% 因Guggenheim证券将其评级从中性上调至买入 目标价285美元 [14] 个股表现与公司动态 - 曼联下跌超过6% 因报告第四季度亏损并下调2026年收入展望 [12] - Uber下跌超过4% 因SEC文件显示CEO出售2860万美元股票 [13] - Roivant Sciences大涨超过12% 其治疗皮肌炎药物在3期试验中达到主要终点 [14] - Zillow上涨超过3% 因Bernstein将其评级从市场表现上调至跑赢大盘 目标价105美元 [14] - 沃尔玛上涨超过2% 因美国银行将目标价从120美元上调至125美元 [15] - MasTec上涨超过1% 因Wolfe Research将其评级从同业表现上调至跑赢大盘 目标价227美元 [15] - Duolingo下跌超过3% 因匈牙利竞争管理局对其商业行为展开调查 [13] - Progressive下跌超过1% 因BMO资本市场将其评级从跑赢大盘下调至市场表现 [13] 国际通胀与利率 - 欧元区8月CPI下修至同比上涨2.0% 核心CPI维持在2.3% [9] - 英国8月CPI同比上涨3.8%与7月持平 核心CPI从3.8%放缓至3.6% [9] - 利率互换市场定价显示ECB在10月30日会议降息25个基点的概率为2% [9] - 10年期德国国债收益率下降1.5个基点至2.678% 英国国债收益率下降1.6个基点至4.623% [8] 经济数据预期 - 预计周四公布的周度初请失业金人数将减少2.3万人至24万人 [5]

Roivant Sciences Ltd ROIV and Priovant Therapeutics released results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM).Dermatomyositis is a chronic autoimmune disorder causing muscle inflammation and a distinctive skin rash, often purple or reddish, on areas like the face, knuckles, and upper chest.Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary en ...

美股市场表现 - 美股涨跌互现 道琼斯指数上涨超过200点 [1] Lyft Inc - 与Waymo宣布扩展至纳什维尔计划 Lyft Flexdrive将管理Waymo全自动驾驶车辆 [1] - 股价大幅上涨13.5%至22.92美元 [1] New Fortress Energy Inc - 与波多黎各政府达成长期天然气供应协议 [3] - 股价飙升32.3%至2.6501美元 [3] Oruka Therapeutics Inc - 公布ORKA-001中期第一阶段试验结果 [3] - 宣布1.8亿美元私募配售 [3] - 股价上涨14.1%至17.01美元 [3] Robo.ai Inc - 股价上涨12.9%至1.9190美元 [3] Roivant Sciences Ltd - 与Priovant公布brepocitinib治疗皮肤肌肉疾病的第三阶段试验结果 [3] - 股价上涨12%至15.89美元 [3] Opendoor Technologies Inc - 股价大涨11.1%至9.91美元 [3] Gevo Inc - 股价上涨11.1%至2.1089美元 [3] Blue Gold Limited - 股价上涨10.5%至11.05美元 [3] Workday Inc - Piper Sandler将评级从减持上调至中性 目标价从220美元上调至235美元 [3] - 股价大涨9%至238.63美元 [3] BGM Group Ltd - 股价上涨8.3%至8.90美元 [3] Parsons Corporation - 获得印太反核走私系统部署任务订单 [3] - 股价上涨6.9%至80.64美元 [3] Chagee Holdings Limited - 股价上涨6.7%至18.42美元 [3] Regencell Bioscience Holdings Limited - 股价上涨5.3%至15.07美元 [3] Circle Internet Group - 股价上涨5%至141.57美元 [3] e.l.f. Beauty Inc - 美国银行证券分析师维持买入评级 目标价从135美元上调至160美元 [3] - 股价上涨4.6%至149.91美元 [3]